Lemaitre Vascular (NASDAQ: LMAT) reported Q2 EPS of $0.17, $0.16 better than the analyst estimate of $0.01. Revenue for the quarter came in at $24.9 million versus the consensus estimate of $17.12 million.

Q2 2020 Results

• Sales of $24.9mm, -16% (-24% organic) vs. Q2 2019
• Op. income of $4.9mm, -18%
• Adjusted op. income of $6.1mm, +3% (excludes acquisition-related special items)
• Operating margin of 20%
• Net income of $3.5mm, -24%
• Earnings of $0.17 per diluted share, -25%
• EBITDA of $6.4mm, -11%

Chairman and CEO George LeMaitre said, “Although COVID-19 cut into sales, we right-sized expenses and posted a 20% operating margin. During the quarter we also acquired Artegraft, a dialysis access graft implanted primarily by vascular surgeons.”

GUIDANCE:

Lemaitre Vascular sees Q3 2020 EPS of $0.17-$0.26, versus the consensus of $0.08. Lemaitre Vascular sees Q3 2020 revenue of $30.5-34.5 million, versus the consensus of $20.94 million.

For earnings history and earnings-related data on Lemaitre Vascular (LMAT) click here.